CompaniesMirImmune

MirImmune

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

0

As Collaborator

3

Total Enrollment

144

By Phase

NA: 3

By Status

COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
Today
NCT05770076
NCT05804422
NCT06352697
Hover over trial bars to see details

Recent Trials

NCT05770076Collaborator
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study)
NACompleted
55 participants
Started: Feb 1, 2023 · Completed: Dec 31, 2023
NCT05804422Collaborator
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)
NACompleted
39 participants
Started: Feb 1, 2023 · Completed: Dec 31, 2023
NCT06352697Collaborator
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
NACompleted
50 participants
Started: Feb 1, 2023 · Completed: Dec 31, 2023
Related Companies
Rxi Pharma
acquired